SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease

Condition:   Early Parkinson's Disease Interventions:   Drug: PT320 2.0mg Placebo;   Drug: PT320 2.0 mg;   Drug: PT320 2.5 mg Sponsor:   Peptron, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials